Archive for January, 2007
January 31st, 2007. Inhaled nitric oxide for acute right-ventricular dysfunction after extrapleural pneumonectomy
Inhaled nitric oxide decreases right-ventricular afterload and improves cardiac index by selectively decreasing pulmonary vascular resistance without causing systemic hypotension. We report the use of inhaled nitric oxide in a patient with acute right-ventricular dysfunction after extrapleural pneumonectomy.
January 27th, 2007. Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma
The results indicate that pemetrexed used in combination with cisplatin significantly increases the length of survival, when compared with cisplatin alone. Further research is needed into the optimum treatment regimen for pleural mesothelioma.
January 27th, 2007. Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma
Only IAP-1 and livin protein was expressed in the nucleus of MPM tumours. These results provide the rationale for additional study of this gene family in MPM and cancer in general.
January 27th, 2007. Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma
5 pg/ml) higher in MPM patients (n=6) prior to surgical tumour debulking compared with those after surgery (median 0 pg/ml). These results when combined with previous observations by our laboratory and others strongly suggest that IAPs act synergistically with TNF family members to promote survival of MPM tumour cells after exposure to cisplatin and possibly other chemotherapeutic drugs.
January 27th, 2007. A Phase I and Pharmacokinetic Study of Pemetrexed Plus Irinotecan in Patients with Advanced Solid Malignancies
Conclusions: The pemetrexed/irinotecan regimen is well tolerated in patients with advanced solid malignancies at clinically relevant single-agent doses. The recommended dose level of pemetrexed/irinotecan for subsequent disease-directed evaluations involving lightly pretreated patients is 500/350 mg/m2 every 3 weeks with vitamin supplementation.
January 27th, 2007. Pericardial cytopathology
Among the 57 pericardial tumors, 51 (89%) were metastatic carcinomas--included 42 (73%) adenocarcinomas--, 5 (9%) were malignant lymphomas and one (2%) was a malignant mesothelioma. Cytology of pericardial effusion with ancillary studies enables rapid cytodiagnosis as specific as histodiagnosis provided by biopsy.
January 26th, 2007. Survey of surgical treatment of malignant pleural mesothelioma in Japan
086) with a marginal significance, indicating that complete surgical resection of the tumor and perioperative adjuvant therapy could be effective treatment for MPM in Japan. Thus, the development of multimodality therapy including surgical treatment for this disease may be required to improve surgical results of MPM patients.
Posted in Biphasic or Mixed, Chemotherapy, Determining Efficacy, Epithelioid, Extrapleural Pneumonectomy (EPP), Full Archive, General, Pleural, Pleurectomy/decortication, Sarcomatoid, Surgery, Survival, Treatment, Trimodality Therapy, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
January 26th, 2007. Preoperative assessment and surgical indication for malignant pleural mesothelioma
Among 5 consective patients who received the preoperative surgical staging during past 10 months, 1 patient was judged not to be a surgical candidate due to the presence of contralateral pleural metastasis. In conclusion, this surgical staging is a useful preoperative evaluation to prevent an unnecessary operation.
January 26th, 2007. Malignant pleural mesothelioma
4% and the median survival time in patients with epithelial mesothelioma was 30. 6 months.
Posted in Biphasic or Mixed, Chemotherapy, Diagnosis & Differentiation, Full Archive, Pleural, Pleural Biopsy, Sarcomatoid, Survival, Treatment, Type of Assessment:, Type of Mesothelioma:, desmoplastic, thoracoscopy | No Comments »
January 26th, 2007. Diffuse malignant pleural mesothelioma
Median survival time after diagnosis was 3 (range, 0 to 51) months. Of the 11 patients, 7 (64%) died within 6 months after the first presentation, and only 1 (9%) lived longer than 2 years after diagnosis.
Posted in Biphasic or Mixed, Chemotherapy, Epithelioid, Extrapleural Pneumonectomy (EPP), Full Archive, Intrapleural Chemotherapy, Pleural, Sarcomatoid, Surgery, Survival, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
January 26th, 2007. Extrapleural pneumonectomy for malignant pleural mesothelioma
3%, respectively. EPP for strictly selected patients has been successful in improving survival of patients with negative-node, epithelial type and negative residual tumors.
January 26th, 2007. Extrapleural pneumonectomy with wide resection of the chest wall, diaphragm, and pericardium for malignant pleural mesothelioma
Furthermore, extrapleural pneumonectomy with wide resection of the chest wall minimizes the resulting dead space, thereby minimizing the risk of postoperative hemorrhage and empyema. We consider that this procedure can be applied for malignant mesothelioma patients, especially those who have pleural masses at costophrenic angle.
January 26th, 2007. Sarcomatoid pleural mesothelioma presenting as posterior mediastinal tumor with dysphagia
The patient died of multiple organ failure on the 1st postoperative day. We report extremely rare cases of sarcomatoid mesothelioma that appeared to be posterior mediastinal tumor before surgery, and discuss the difficulty of diagnosing sarcomatoid mesothelioma with atypical clinical manifestations.
January 26th, 2007. Heparanase expression: a potential ancillary diagnostic tool for distinguishing between malignant cells and reactive mesothelium in body cavity effusions
Conclusions: Our results suggest that heparanase may be of value as a complementary component in a diagnostic panel of markers, contributing to its reliability and accuracy.
January 26th, 2007. Talc mediates angiostasis in malignant pleural effusions via endostatin induction
In conlusion, talc alters the angiogenic balance in the pleural space from a biologically active and angiogenic environment to an angiostatic milieu. Functional improvement following talc poudrage in patients with malignant pleural effusions may, in part, reflect these alterations in the pleural space.
January 26th, 2007. A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes
Initially linked solely to the exposure to a fibrous mineral, erionite, recent studies by scientists from Turkey and the United States have shown that erionite causes mesothelioma mostly in families that are genetically predisposed to mineral fibre carcinogenesis. This manuscript reports, through the eyes of one of the researchers, the resulting scientific advances that have come from these studies and the social improvements that were brought about by both the scientists and members of the Turkish Government.
January 24th, 2007. Immunotherapy and malignant mesothelioma: clinical perspectives
Thus, immunotherapy of cancer is undoubtedly a highly promising but also very challenging approach in the treatment of a disease that has slipped through the defence lines of the immune system. This article will review past and recent developments of such a clinical strategy.
January 24th, 2007. Malignant pleural cancers mortality and compensated cases for asbestos related diseases in Lazio municipalities (1980-2001)
Conclusions: Epidemiological surveillance of incident cases of malignant mesothelioma in the Lazio Region and the investigation of modalities of asbestos exposure are urgently needed for prevention of occupational diseases.
January 24th, 2007. Malignant Mesothelioma: A Case Presentation and Review
This article describes a rare subtype of mesothelioma and illustrates the difficulty in establishing the diagnosis. Also included is a discussion of the clinical features, diagnostic dilemmas, and unsatisfactory outcome associated with this disease.
January 20th, 2007. Metastatic malignant pleural mesothelioma to the breast
Further immunohistochemical study was performed and the tumor cells were positive for low and high molecular weight cytokeratin, thrombomodulin and focally positive for CEA. The final histologic diagnosis was metastatic malignant mesothelioma.
|
|  |
